Efficacy of pHA130 Hemoadsorption for 4 Hours (p4H Study)

This is an open-label, randomized, crossover study to evaluate the efficacy of extending the duration of hemoadsorption (HA) combined with hemodialysis (HD) from 2 hours to 4 hours for clearing protein-bound uremic toxins, such as Indoxyl Sulfate (IS), in stable maintenance hemodialysis patients. Patients will be randomized to receive either 2-hour HA or 4-hour HA once a week for 8 weeks, then cross over to the other treatment for another 8 weeks after a 2-week washout period. The primary endpoint is the reduction rate of IS.

NCT Number	NCT07111260
Lead Sponsor	Peking University People's Hospital
Conditions	End Stage Renal Disease on Dialysis
Enrollment	34 participants
Start Date	2025-07-01
Primary Completion	2026-03 (estimated)
Study Completion	2026-05 (estimated)
Updated on ClinicalTrials.gov	2025-08-08